244 related articles for article (PubMed ID: 23723333)
1. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.
Curtit E; Nerich V; Mansi L; Chaigneau L; Cals L; Villanueva C; Bazan F; Montcuquet P; Meneveau N; Perrin S; Algros MP; Pivot X
Oncologist; 2013 Jun; 18(6):667-74. PubMed ID: 23723333
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.
Shen Q; Sahin AA; Hess KR; Suki D; Aldape KD; Sawaya R; Ibrahim NK
Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405
[TBL] [Abstract][Full Text] [Related]
3. Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes.
Khande TA; Joshi AR; Khandeparkar SGS; Kulkarni MM; Gogate BP; Kakade AR; Sahu PD; Khillare CD
Indian J Cancer; 2020; 57(2):190-197. PubMed ID: 32445323
[TBL] [Abstract][Full Text] [Related]
4. Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.
Walter V; Fischer C; Deutsch TM; Ersing C; Nees J; Schütz F; Fremd C; Grischke EM; Sinn P; Brucker SY; Schneeweiss A; Hartkopf AD; Wallwiener M
Breast Cancer Res Treat; 2020 Aug; 183(1):137-144. PubMed ID: 32613540
[TBL] [Abstract][Full Text] [Related]
5. Age related influence of triple receptor status on metastatic breast cancer post relapse survival.
Todorovic-Rakovic N; Neskovic-Konstantinovic Z
J BUON; 2013; 18(4):851-8. PubMed ID: 24344008
[TBL] [Abstract][Full Text] [Related]
6. Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment.
Liu J; Deng H; Jia W; Zeng Y; Rao N; Li S; Jin L; Wu J; Song E; Su F
J Cancer Res Clin Oncol; 2012 May; 138(5):837-42. PubMed ID: 22290394
[TBL] [Abstract][Full Text] [Related]
7. Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Finn RS; Press MF; Dering J; O'Rourke L; Florance A; Ellis C; Martin AM; Johnston S
Clin Cancer Res; 2014 Feb; 20(3):736-43. PubMed ID: 24198242
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), Ki67 changes and their clinical significance between primary breast cancer and metastatic tumors.
Qi G; Zhang X; Gai X; Yan X
PeerJ; 2024; 12():e17377. PubMed ID: 38766488
[TBL] [Abstract][Full Text] [Related]
9. Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study.
Kaidar-Person O; Meattini I; Jain P; Bult P; Simone N; Kindts I; Steffens R; Weltens C; Navarria P; Belkacemi Y; Lopez-Guerra J; Livi L; Baumert BG; Vieites B; Limon D; Kurman N; Ko K; Yu JB; Chiang V; Poortmans P; Zagar T
Breast Cancer Res Treat; 2018 Jan; 167(2):479-483. PubMed ID: 28975433
[TBL] [Abstract][Full Text] [Related]
10. HER-2, ER, PR status concordance in primary breast cancer and corresponding metastatic lesion in lymph node in Chinese women.
Li MH; Hou CL; Wang C; Sun AJ
Pathol Res Pract; 2016 Apr; 212(4):252-7. PubMed ID: 26899763
[TBL] [Abstract][Full Text] [Related]
11. Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients.
Yang YF; Liao YY; Yang M; Peng NF; Xie SR; Xie YF
Med Oncol; 2014 Oct; 31(10):214. PubMed ID: 25216864
[TBL] [Abstract][Full Text] [Related]
12. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.
Finn RS; Press MF; Dering J; Arbushites M; Koehler M; Oliva C; Williams LS; Di Leo A
J Clin Oncol; 2009 Aug; 27(24):3908-15. PubMed ID: 19620495
[TBL] [Abstract][Full Text] [Related]
14. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
Monaco SE; Wu Y; Teot LA; Cai G
Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
[TBL] [Abstract][Full Text] [Related]
15. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.
Peng L; Zhang Z; Zhao D; Zhao J; Mao F; Sun Q
Pathol Oncol Res; 2021; 27():599894. PubMed ID: 34257555
[No Abstract] [Full Text] [Related]
16. Identification of oestrogen, progesterone receptor and human epidermal growth factor receptor 2 expression in mediastinal metastases of breast cancer obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
Serra P; Sanz-Santos J; Castellà E; Cirauqui B; Andreo F; Llatjós M; Avila M; Margelí M; Serrano L; Centeno C; Quiroga V; Torky M; Ruiz-Manzano J
Cytopathology; 2018 Feb; 29(1):35-40. PubMed ID: 29119620
[TBL] [Abstract][Full Text] [Related]
17. Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution.
Chen R; Qarmali M; Siegal GP; Wei S
Mod Pathol; 2020 Dec; 33(12):2499-2506. PubMed ID: 32620918
[TBL] [Abstract][Full Text] [Related]
18. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.
Yeung C; Hilton J; Clemons M; Mazzarello S; Hutton B; Haggar F; Addison CL; Kuchuk I; Zhu X; Gelmon K; Arnaout A
Cancer Metastasis Rev; 2016 Sep; 35(3):427-37. PubMed ID: 27405651
[TBL] [Abstract][Full Text] [Related]
19. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain.
Rao PS; Labhart M; Mayhew SL; Thirumala S; Rao US
Tumour Biol; 2014 Jul; 35(7):7267-73. PubMed ID: 24777335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
